Vestal Point Capital LP grew its stake in Ventyx Biosciences, Inc. (NASDAQ:VTYX - Free Report) by 15.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,000,000 shares of the company's stock after acquiring an additional 275,000 shares during the period. Vestal Point Capital LP owned 2.83% of Ventyx Biosciences worth $4,380,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors also recently modified their holdings of the company. Catalina Capital Group LLC bought a new position in shares of Ventyx Biosciences in the fourth quarter worth about $25,000. AXQ Capital LP bought a new position in shares of Ventyx Biosciences in the fourth quarter worth about $29,000. Palumbo Wealth Management LLC raised its stake in shares of Ventyx Biosciences by 97.1% in the fourth quarter. Palumbo Wealth Management LLC now owns 23,932 shares of the company's stock worth $52,000 after acquiring an additional 11,792 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Ventyx Biosciences by 76.0% in the fourth quarter. MetLife Investment Management LLC now owns 26,731 shares of the company's stock worth $59,000 after acquiring an additional 11,543 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in shares of Ventyx Biosciences by 23.3% in the fourth quarter. Wells Fargo & Company MN now owns 41,170 shares of the company's stock worth $90,000 after acquiring an additional 7,768 shares during the last quarter. 97.88% of the stock is owned by institutional investors.
Ventyx Biosciences Stock Performance
Shares of NASDAQ VTYX traded down $0.13 during trading on Friday, reaching $1.69. The company had a trading volume of 1,361,034 shares, compared to its average volume of 1,333,964. Ventyx Biosciences, Inc. has a 52 week low of $0.78 and a 52 week high of $5.66. The stock has a market cap of $120.26 million, a PE ratio of -0.72 and a beta of 0.73. The business's 50 day moving average price is $1.21 and its 200-day moving average price is $1.74.
Ventyx Biosciences (NASDAQ:VTYX - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.39) earnings per share for the quarter, topping analysts' consensus estimates of ($0.48) by $0.09. Equities analysts anticipate that Ventyx Biosciences, Inc. will post -2.09 earnings per share for the current year.
Ventyx Biosciences Company Profile
(
Free Report)
Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.
Further Reading
Before you consider Ventyx Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ventyx Biosciences wasn't on the list.
While Ventyx Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
